Search research articles
Contact Us
Filters
Showing results (111-120 of 142) with videos related to
Page
of 15
Sort By:
Anticancer Research
|
September 1, 1986
Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology
R Paridaens, D Becquart, J Michel, et al.
Revue Medicale De Liege
|
April 19, 2000
[Epidemiological aspects, risk factors, and detection of pancreatic cancer]
M Delforge, O Plomteux, J C Demoulin, et al.
Cancer Treatment Reviews
|
September 1, 1983
Ifosfamide (with mesna), vincristine and cis-platinum for carcinoma of the head and neck
C Focan, S Le Hung, R Bays-Gallaix, et al.
Anticancer Research
|
July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report
L Longrée, C Focan, J Bury, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
F Levi, B Perpoint, C Garufi, et al.
Anticancer Research
|
February 24, 2001
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer
C Focan, J Bury, M Beauduin, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 1989
Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I)
C Focan, A Baudoux, M Beauduin, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer
R Paridaens, C Focan, J Michel, et al.
Anticancer Research
|
September 1, 1986
Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients)
C Focan, A Baudoux, M Beauduin, et al.
Revue Medicale De Liege
|
May 24, 2000
[Chronopharmacologic approach to the administration of anticancer agents in pancreatic adenocarcinoma. Pilot experience]
C Focan, F Kreutz, D Focan-Henrard, et al.
Page
of 15
Search research articles
Search
Showing results (111-120 of 142) with videos related to
Sort By:
Page
of 15
Anticancer Research
|
September 1, 1986
Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology
R Paridaens, D Becquart, J Michel, et al.
Revue Medicale De Liege
|
April 19, 2000
[Epidemiological aspects, risk factors, and detection of pancreatic cancer]
M Delforge, O Plomteux, J C Demoulin, et al.
Cancer Treatment Reviews
|
September 1, 1983
Ifosfamide (with mesna), vincristine and cis-platinum for carcinoma of the head and neck
C Focan, S Le Hung, R Bays-Gallaix, et al.
Anticancer Research
|
July 1, 1995
Levamisole adds granulocyte toxicity to 5FU-based chemotherapies in adjuvant treatment of Dukes B-C colorectal cancer. A preliminary report
L Longrée, C Focan, J Bury, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 1, 1993
Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate
F Levi, B Perpoint, C Garufi, et al.
Anticancer Research
|
February 24, 2001
Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer
C Focan, J Bury, M Beauduin, et al.
Acta Oncologica (Stockholm, Sweden)
|
January 1, 1989
Adjuvant treatment with high dose medroxyprogesterone acetate in node-negative early breast cancer. A 3-year interim report on a randomized trial (I)
C Focan, A Baudoux, M Beauduin, et al.
Cancer Chemotherapy and Pharmacology
|
January 1, 1990
Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer
R Paridaens, C Focan, J Michel, et al.
Anticancer Research
|
September 1, 1986
Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate (HD-MPA) adjuvant treatment for primary node positive breast cancer (analysis of 100 patients)
C Focan, A Baudoux, M Beauduin, et al.
Revue Medicale De Liege
|
May 24, 2000
[Chronopharmacologic approach to the administration of anticancer agents in pancreatic adenocarcinoma. Pilot experience]
C Focan, F Kreutz, D Focan-Henrard, et al.
Page
of 15